Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL system, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*

iLink™ is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help you preserve your patients’ vision.

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.
Transforming the standard of care for progressive keratoconus

In clinical studies, cross-linking–treated eyes showed increasing improvement in $K_{\text{max}}$ from month 3 through month 12, while in untreated, sham eyes, $K_{\text{max}}$ demonstrated steepening.\(^1\)

### Change From Baseline ($K_{\text{max}}$)–Progressive Keratoconus Patients*\(^1\)

<table>
<thead>
<tr>
<th></th>
<th>SHAM STUDY 1</th>
<th>SHAM STUDY 2</th>
<th>CXL STUDY 1</th>
<th>CXL STUDY 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Month 1</strong></td>
<td>-2.0</td>
<td>-1.5</td>
<td>-1.0</td>
<td>-0.5</td>
</tr>
<tr>
<td><strong>Month 3</strong></td>
<td>-1.0</td>
<td>-0.5</td>
<td>0.0</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Month 6</strong></td>
<td>-1.5</td>
<td>-1.0</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Month 12</strong></td>
<td>-2.0</td>
<td>-1.5</td>
<td>1.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

*Post-baseline missing data were imputed using last available $K_{\text{max}}$ value. For the sham study eyes that received CXL treatment after baseline, the last $K_{\text{max}}$ measurement recorded prior to receiving CXL treatment was used in the analysis for later time points. In Study 3, 4 patients in the CXL group had missing baseline $K_{\text{max}}$ value and were excluded from the analysis.

CXL=corneal cross-linking.

**Cross-linking using UVA and riboflavin**\(^2\)

- Creates new corneal collagen cross-links
- Results in a shortening and thickening of collagen fibrils
- Leads to stiffening of the cornea

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Offers a proven safety profile

iLink™ keeps keratoconus from calling the shots

Left untreated, 1 in 5 patients with progressive keratoconus may require a corneal transplant. More than half of these patients could need multiple transplants within 20 years.3,4

OVER 400,000 CROSS-LINKING PROCEDURES HAVE BEEN PERFORMED WORLDWIDE WITH OUR EQUIPMENT®

APPROVED IN 2016 IN THE UNITED STATES FOLLOWING 2 SUCCESSFUL PHASE III TRIALS1

Understanding the science

iLink™ proprietary procedure6

- iLink™ combines ultraviolet light with ambient oxygen and Photrexa® bioactivated ophthalmic solution
- Absorption of UVA by Photrexa® generates radical riboflavin to form cross-links
- Precise, metered UV light delivery with the KXL system
- Backed by 20 years of science to achieve the right formulation

Both the American Academy of Ophthalmology and the Cornea Society recommend cross-linking for the treatment of progressive keratoconus.7,8

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Diagnose and treat progressive keratoconus

Keratoconus may be vastly underdiagnosed, underestimated, and underserved

Left unchecked, progression can lead to a higher risk of vision loss, significantly reduced vision quality of life, and the potential need for a corneal transplant.

Prevalence was as high as 1 in 375 in a recent Netherlands study, which is 5 to 10 times higher than previously reported.

Onset occurs from 12 years of age through 20 years of age for a vast majority of patients.

Vision loss is associated with anxiety, depression, potential loss of independence, and a heavier burden on family members and/or social services.

Offer your patients the benefits of iLink™

- Peace of mind
- The only therapeutic treatment option for progressive keratoconus
- May reduce or delay the need for more invasive procedures
- One-time procedure widely covered by commercial medical insurance

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Prevalence was as high as 1 in 375 in a recent Netherlands study, which is 5 to 10 times higher than previously reported. \(^1,^2\) Left unchecked, progression can lead to a higher risk of vision loss, significantly reduced vision quality of life, and the potential need for a corneal transplant. \(^10,^11\)

The proprietary iLink™ procedure incorporates:

**The KXL System**
- UVA irradiation: 30 minutes at 3 mW/cm\(^2\)
- Laser alignment for patient positioning
- Wireless control for beam alignment in the X, Y, and Z axes
- Fully integrated stable delivery platform
- Touchscreen operation
- Self-calibration of UVA irradiation intensity

**Photrexa® and Photrexa® Viscous**
- Only FDA-approved bioactivated riboflavin ophthalmic solutions
- Manufactured using validated processes in a state-of-the-art drug manufacturing facility
- GMP-certified material
- Packaged and controlled under GMP standards

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Reimbursement support and tools give patients access to iLink™

**OVER 95% COMMERCIAL INSURANCE COVERAGE**

- Financial feasibility tools available
- National team of dedicated reimbursement experts
- Billing, coding, preauthorization, claims, and appeals resources available
- Flexible options for equipment acquisition
- Uninsured and Medicaid available for qualified patients
- Access to the Photrexa® cross-linking kit via Specialty Pharmacy

For the latest information on reimbursement, including insurers that cover iLink™, visit Glaukos.com. Ask your Glaukos representative about seamlessly integrating iLink™ into your practice.

Cost efficiencies may be possible when iLink™ is performed early in the disease stage

Slowing or halting disease progression with a single outpatient procedure may be a more cost-effective option for patients than ongoing management approaches.¹⁵

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Glaukos is a global pioneer in the ophthalmic market with novel therapies that provide sustainable solutions for important clinical needs.

**Our focus** is to develop and lead the global ophthalmic market with therapies for glaucoma and corneal and retinal diseases through continual innovation and investment.

**Our mission** is to transform treatment and provide therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

**CREATING FIRSTS WITH MANY MORE ON THE HORIZON**

- First minimally invasive glaucoma surgery (MIGS) device commercially available in the United States
- Smallest medical device ever implanted in humans
- First and only FDA-approved procedure proven to slow or halt progression of keratoconus

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
iLink™ slows or halts progression to help you preserve vision

- Only FDA-approved cross-linking procedure
- Wide reimbursement coverage
- Backed by Glaukos comprehensive support

FOR MORE INFORMATION ON iLink™, VISIT GLAUKOS.COM OR CONTACT YOUR GLAUKOS REPRESENTATIVE

REFERENCES:
5. Data on File, Glaukos, Inc.

INDICATIONS
Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the IOL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Corneal collagen cross-linking should not be performed on pregnant women.

IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.
The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelial defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® system, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*

**NOW FROM GLAUKOS**

* Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

**GET THERE IN TIME**

iLink™ is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help you preserve your patients’ vision.

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.
Transforming the standard of care for progressive keratoconus

In clinical studies, cross-linking–treated eyes showed increasing improvement in $K_{\text{max}}$ from month 3 through month 12, while in untreated, sham eyes, $K_{\text{max}}$ demonstrated steepening.¹

### Change From Baseline ($K_{\text{max}}$)–Progressive Keratoconus Patients*¹

<table>
<thead>
<tr>
<th></th>
<th>SHAM STUDY 1</th>
<th>SHAM STUDY 2</th>
<th>CXL STUDY 1</th>
<th>CXL STUDY 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Month 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Month 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Month 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Month 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Post-baseline missing data were imputed using last available $K_{\text{max}}$ value. For the sham study eyes that received CXL treatment after baseline, the last $K_{\text{max}}$ measurement recorded prior to receiving CXL treatment was used in the analysis for later time points. In Study 3, 4 patients in the CXL group had missing baseline $K_{\text{max}}$ value and were excluded from the analysis.

CXL = corneal cross-linking.

---

**Cross-linking using UVA and riboflavin²**

- Creates new corneal collagen cross-links
- Results in a shortening and thickening of collagen fibrils
- Leads to stiffening of the cornea

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Offers a proven safety profile

iLink™ keeps keratoconus from calling the shots

Left untreated, 1 in 5 patients with progressive keratoconus may require a corneal transplant. More than half of these patients could need multiple transplants within 20 years.3,4

OVER 400,000
CROSS-LINKING PROCEDURES HAVE BEEN PERFORMED WORLDWIDE WITH OUR EQUIPMENT5

APPROVED IN 2016
IN THE UNITED STATES FOLLOWING 2 SUCCESSFUL PHASE III TRIALS1

Understanding the science

iLink™ proprietary procedure6

- iLink™ combines ultraviolet light with ambient oxygen and Photrexa® bioactivated ophthalmic solution
- Absorption of UVA by Photrexa® generates radical riboflavin to form cross-links
- Precise, metered UV light delivery with the KXL system
- Backed by 20 years of science to achieve the right formulation

Both the American Academy of Ophthalmology and the Cornea Society recommend cross-linking for the treatment of progressive keratoconus.7,8

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Diagnose and treat progressive keratoconus

Keratoconus may be vastly underdiagnosed, underestimated, and underserved⁹

Left unchecked, progression can lead to a higher risk of vision loss, significantly reduced vision quality of life, and the potential need for a corneal transplant.¹⁰,¹¹

Prevalence was as high as 1 in 375 in a recent Netherlands study, which is 5 to 10 times higher than previously reported.¹²

Onset occurs from 12 years of age through 20 years of age for a vast majority of patients.¹³

Vision loss is associated with anxiety, depression, potential loss of independence, and a heavier burden on family members and/or social services.¹⁰

Offer your patients the benefits of iLink™

- Peace of mind
- The only therapeutic treatment option for progressive keratoconus
- May reduce or delay the need for more invasive procedures¹⁴
- One-time procedure widely covered by commercial medical insurance¹⁵

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Take control with the iLink™ procedure

As a minimally invasive procedure, the iLink™ cross-linking procedure is the new standard of care for progressive keratoconus. With extensive clinical validations, iLink™ is proven safe and efficacious in numerous trials and peer-reviewed publications.1,7

The proprietary iLink™ procedure incorporates:

The KXL System

- UVA irradiation: 30 minutes at 3 mW/cm²
- Laser alignment for patient positioning
- Wireless control for beam alignment in the X, Y, and Z axes
- Fully integrated stable delivery platform
- Touchscreen operation
- Self-calibration of UVA irradiation intensity

Photrexa® and Photrexa® Viscous

- Only FDA-approved bioactivated riboflavin ophthalmic solutions
- Manufactured using validated processes in a state-of-the-art drug manufacturing facility
- GMP-certified material
- Packaged and controlled under GMP standards

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Reimbursement support and tools give patients access to iLink™

OVER 95% COMMERCIAL INSURANCE COVERAGE

Financial feasibility tools available  National team of dedicated reimbursement experts  Billing, coding, preauthorization, claims, and appeals resources available

Flexible options for equipment acquisition  Uninsured and Medicaid available for qualified patients  Access to the Photrexa® cross-linking kit via Specialty Pharmacy

For the latest information on reimbursement, including insurers that cover iLink™, visit Glaukos.com. Ask your Glaukos representative about seamlessly integrating iLink™ into your practice.

Cost efficiencies may be possible when iLink™ is performed early in the disease stage

Slowing or halting disease progression with a single outpatient procedure may be a more cost-effective option for patients than ongoing management approaches.15

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
Glaukos is a global pioneer in the ophthalmic market with novel therapies that provide sustainable solutions for important clinical needs.

Our focus is to develop and lead the global ophthalmic market with therapies for glaucoma and corneal and retinal diseases through continual innovation and investment.

Our mission is to transform treatment and provide therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

Creating Firsts with Many More on the Horizon

- First minimally invasive glaucoma surgery (MIGS) device commercially available in the United States
- Smallest medical device ever implanted in humans
- First and only FDA-approved procedure proven to slow or halt progression of keratoconus

See back cover for Important Safety Information and visit livingwithkeratoconus.com for full prescribing information.
iLink™ slows or halts progression to help you preserve vision

• Only FDA-approved cross-linking procedure
• Wide reimbursement coverage
• Backed by Glaukos comprehensive support

REFERENCES:
5. Data on File, Glaukos, Inc.

INDICATIONS
Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the IOL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.
Corneal collagen cross-linking should not be performed on pregnant women.

IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.
The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.
These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.